Vyndamax
Payments companies reported to CMS as associated with Vyndamax. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Vyndamax, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Vyndamax
These are the largest totals companies reported as associated with Vyndamax. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Mazen Hanna | Cleveland, OH | Cardiovascular Disease | $25,147.91 |
| Ronald Witteles | Stanford, CA | Advanced Heart Failure and Transplant Cardiology | $15,866.70 |
| Mathew Maurer | New York, NY | Advanced Heart Failure and Transplant Cardiology | $15,099.11 |
| Saurabh Malhotra | Buffalo, NY | Cardiovascular Disease | $13,938.24 |
| David Wolinsky | Weston, FL | Cardiovascular Disease | $13,122.00 |
| Joshua Mitchell | Saint Louis, MO | Cardiovascular Disease | $12,641.39 |
| Sumeet Mitter | New York, NY | Cardiovascular Disease | $12,218.10 |
| Rajeev Mohan | La Jolla, CA | Advanced Heart Failure and Transplant Cardiology | $12,092.97 |
| Vasvi Singh | Overland Park, KS | Cardiovascular Disease | $11,769.52 |
| Michel Khouri | Durham, NC | Cardiovascular Disease | $11,134.65 |
Prescribed Vyndamax?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.